The synthesis of novel aza-1,7-annulated indoles was achieved and these were converted to indolocarbazoles that proved to be potent kinase inhibitors. These compounds were also evaluated in a human colon carcinoma cell line and proved to be good antiproliferative agents.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.bmcl.2004.05.088 | DOI Listing |
J Intellect Dev Disabil
September 2022
Faculty of Psychology and Neuroscience, Maastricht University, Maastricht, The Netherlands.
Background: In forensic settings, patients with intellectual disabilities are overrepresented. A relative novel treatment approach for this population is schema therapy. The goals of schema therapy for offenders with intellectual disabilities are to reduce maladaptive emotional states and to reinforce healthy emotional states and enhancing the patient's ability to ask for help.
View Article and Find Full Text PDFParkinsonism Relat Disord
January 2025
Center for Neurological Restoration, Neurological Institute, Cleveland Clinic, Ohio, United States. Electronic address:
Clin Chim Acta
January 2025
College of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou, China. Electronic address:
Ann Oncol
January 2025
Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Background: The availability and affordability of safe, effective cancer therapies are core requirements for effective cancer control. Global disparities exist in access, however, yielding unequal cancer outcomes. The goal of this study was to provide updated data regarding the formulary availability, out-of-pocket costs, and accessibility of cancer medicines in countries across the full spectrum of economic development areas.
View Article and Find Full Text PDFDig Liver Dis
January 2025
Department of Pathology, Beijing Ditan Hospital, Captial Medical University, Beijing 100015, PR China. Electronic address:
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!